Overall, patients with YAOS showed a poor response to NSAIDs (n=7/9), colchicine (n=6/8) and/or anti-TNFa treatment (n=3/4), while more than half of the patients receiving steroids (n=6/10) and most of the patients receiving anti–IL-1 agents (n=3/5) had a complete resolution of symptoms and normalization of laboratory parameters. Here, IL1B is linked to Yao syndrome.